key: cord-0860686-gnumt27q
authors: Chang, Wen-Han
title: A review of vaccine effects on women in light of the COVID-19 pandemic
date: 2020-09-11
journal: Taiwan J Obstet Gynecol
DOI: 10.1016/j.tjog.2020.09.006
sha: 5d5d679c87211d5e4c0d0375c2c83c3cd444a99f
doc_id: 860686
cord_uid: gnumt27q

The pandemic situation triggered by the spread of COVID-19 has caused great harm worldwide. More than six million people have been infected, and more than 360,000 of them have died. This is the worst catastrophe suffered by mankind in recent history. In the face of this severe disaster, people all over the world are frightened of the prospect of facing an outbreak or an annual recurrence. However, the development of a vaccine will help control the impact of COVID-19. Women in particular have been more seriously affected by the pandemic. Since the pressure and physical load they suffer are often greater than what men endure, women are more threatened by COVID-19. Though women have a poorer quality of life and work and face worse economic conditions, they also tend to have better physiological immunity than men, which can ease the effect of COVID-19. The early development of a vaccine against COVID-19 is an important issue that must take into consideration women’s better immune response to the virus along with the technique of hormone regulation. Relevant research has been conducted on female-specific vaccines in the past, and women’s issues were considered during those clinical trials to ensure that complications and antibody responses were positive and effective in women. National policies should also propose good strategies for women to be vaccinated. This could improve consciousness, give women a better vaccination experience, enhance their willingness to vaccinate, and protect them from COVID-19 infection.

The research team of the American Society for Microbiology (ASM 2016) presented observations on the differences in the effectiveness of vaccines between men and women [45] .

Katie Flanagan of the University of Tasmania, Australia, published another example of a gender vaccine difference [46] . The study found that a tuberculosis vaccine inhibits the anti-inflammatory protein in girls, thus enhancing the effectiveness of the immune response to the vaccine [47] .

The effect of hormones on the immune response has long been noticed in the field of biomedicine [48] . For example, estrogen can activate cells involved in antiviral reactions, and testosterone can inhibit inflammation [49, 50] . Recently, Derezt et.al. conducted experiments on nasal epithelial cells and found that estrogen can inhibit the replication of influenza A virus in female cells [51] . Additionally, many studies found the TLR7 gene located on the X chromosome, and one of the functions of the protein made by this gene is to detect viruses and initiate immune responses and is found to cause stronger immune responses in women than men. The exact reason for this is not yet known by biologists [52, 53] .

Since the immune responses of both genders are different, should gender be considered in vaccine development? Many biologists believe that it most certainly should be. In 2014, the NIH required researchers to indicate and examine gender differences when reporting the results of animal experiments [54] . In addition, the Audit Department of the US government recommended that the study of human body implemented on gender information should be open and transparent, and gender differences should be analyzed [55, 56] .

The measles infection is the main cause of death among children. Although the measles virus has been controlled and eliminated in the modern day, there may be significant changes in measles epidemiology in the coming decades. With the gradual reduction of antibodies in the mother's body, the probability of infants suffering from measles will be higher and higher. a public vaccination program for women aged 12-26 years [75] [76] [77] . British public health points out that the coverage rate of the HPV vaccine in British women aged 12-13 years is close to 87% [78] [79] [80] .

The ACE2 receptor is the key for SARS coronavirus to enter human cells [81, 82] . After the outbreak of COVID-19, research on its nature confirmed that it also entered into human cells using the ACE2 receptor. A virus channel was established in mice to develop "ACE2 gene-cloned mice," which can be used for new vaccines and drug tests along with screenings to prove whether a vaccine is effective. Evidence from a large-scale study indicates that the concentration of ACE2 in the blood of men is higher than in women, which makes men more susceptible to COVID-19 than women [83] [84] [85] . The official US report found that the death rate is 55% for men and 45% for women. From a biological and immunological point of view, women usually have a stronger and faster immune response than men. While some researchers discovered that estrogen and testosterone may affect the novel coronavirus response [86, 87] , it has been found in animal experiments that male hormones have a higher affinity for ACE2. It means that COVID-19 is more likely to attack male cells, which is important to consider to the future for development of vaccines by the way avoiding the coronavirus from entering the cell through the ACE2 receptor [88] [89] [90] .

Studies in West African countries also point out that girls' antibody loss rate is faster, which causes them to be infected with measles earlier than boys, and those girls need to strengthen vaccine injections in the future, otherwise may get infection recurrently [91, 92] . Children who are not vaccinated against measles or who do not respond well to the vaccine, if not vaccinated continuously, will become the targets of infection in the future. Above problem has already appeared in West Africa. There were many pregnant young women found infected with measles, H7N9 avian influenza A virus pneumonia and ARDS can cause the death of the fetus or mother, with the hope of further vaccine development to prevent [93, 94] . Garenne (1994) pointed out that the proportion of females who died of the measles vaccine was higher than that of males [95] . Garenne believed that this was the result of hormone differences. In addition to exposure intensity and transmission mode, a child's own health conditions may also affect the death rate of the measles vaccine. People with chronic diseases such as Kwashiorkor and tuberculosis (TB) have a high risk of death in relation to the measles vaccine. Vaccination with other unrelated vaccines may also affect the severity of the measles infection in children [96, 97] . In the Guinea Bissau study, it was found that if girls had J o u r n a l P r e -p r o o f recently received a live vaccine, the proportion of them who needed to be hospitalized after a measles infection was lower than that of boys, but if they had recently received an inactive vaccine, the opposite result occurred [98] . The severity of the symptoms of girls and boys is affected by age and social environment. In European society, young boys are more likely to be exposed to the virus, so the mortality rate is higher. Regular measles vaccination and prevention education are the control measures. The main mode of measles infection. Some studies have pointed out that, in addition to measles prevention, measles vaccination also has the effect of promoting immunity, which has a significant impact on women [99, 100] .

Vaccine development will be a particularly useful weapon against COVID-19. For more than two centuries, human beings have successfully used this medical technology to fight against viruses such as measles and influenza, proving that vaccines can stop disease outbreaks before they spread [101, 102] . COVID-19, according to the WHO, currently has at least 62 candidate vaccines under development. The evidence shows that patients infected by the novel coronavirus can produce antibodies in the blood that can attack and neutralize the COVID-19

virus, so experts are optimistic that a vaccine will be successfully developed [103] .

Considering the history of vaccine development, it will take a year or more before the world sees a COVID-19 vaccine [104] . The mumps vaccine is regarded as the fastest approved vaccine, but it was four years between the initial collection of virus samples and obtaining a drug license in 1967 [105] . There are three phases of clinical trials, and vaccine experts believe that COVID-19 candidate vaccine trials are completed. In the first phase, the results will not be seen until at least this autumn or the spring of 2021 [106] [107] [108] .

There is a good reason to spend time testing vaccine safety. For example, in model experiments, some preliminary vaccines for SARS (a related coronavirus) actually enhance the disease. Peter Hotez thinks that completing the vaccine in a year to 18 months is unprecedented. Approaching the situation too anxiously could affect the health of the injected person, and researchers must be careful to evaluate the development of a vaccine. Traditional techniques rely on the immune system to respond to pathogen-specific proteins, which usually coat the surface of the virus, causing the body to react and produce many antibodies [109, 110] .

Vaccine developers have found that they do not need a complete virus and can use a single protein as a substitute to produce a strong immune response in the human body. Maria Elena Bottazzi believes that vaccines based on these proteins are easier and cheaper to make, and this has become the most commonly used method by medical professionals [111, 112] .

Another study explored the vaccination rate of HPV among female college students in Greece and the factors for predicting vaccination. It was found that the factors for positive prediction of vaccination included higher education level of self and parents and easy access to health care services [150] . An previous study of women who received a free HPV vaccine found that at least one dose was significantly related to women's marital status, higher socioeconomic status, as well as whether they lived in a remote area [151] . Kessels et al. conducted a systematic study on the HPV vaccination among adolescent girls and its underlying factors [152] . The results showed that higher vaccination behavior was related to older age, access to a medical service provider as an information source, and a positive attitude toward vaccination [153] [154] [155] .

A national survey was conducted to investigate the influencing factors on a parent's willingness to allow adolescent girls to receive the HPV vaccine. The results showed that the safety and efficacy of the vaccine were related factors affecting acceptability [156] . Marlow et al. (2009) studied young girls in the UK aged 16-19 years and pointed out that higher self-awareness of disease is related to vaccine acceptance [157] . The study showed that the higher the "general or special interest of self-awareness" score, the more likely the subject was to be vaccinated, and the higher the "special obstacle of self-awareness" score, the more unlikely the subject was to be vaccinated. The score obtained was a significant predictor of receiving the HPV vaccine [158] . A study of women between the ages of 19-26 in the United States found that "getting a doctor's advice and discussing the HPV vaccine with doctors" had an overwhelming predictive power, while student identity and personal perception of vaccine importance also had a good predictive power for vaccination [159, 160] . Krawczyk et al. provided the health belief model as the framework to investigate female college students and found that the negative impact of vaccination on health, doctor's advice, and positive attitude toward vaccination were significant related factors of HPV vaccination [161] [162] [163] .

According to a study in Taiwan, to a certain extent, women's knowledge about vaccination action clues mainly comes from schools, media, and health units. Women's awareness of disease, action clues, vaccination health beliefs, and vaccination action intentions are significantly higher than men's [164] . According to the vaccination analysis by the staff of Taiwan's statistics and medical institutions, the main concerns about influenza vaccination are fear of side effects after vaccination (24.2%), doubt about vaccine safety (15.5%), and belief that influenza will still be acquired after vaccination (12.2%) [165] . Of the subjects who participated in this analysis, 70.1% believed that influenza vaccination should be carried out every year. However, 41.2% believed pregnant women did not need to be vaccinated against J o u r n a l P r e -p r o o f the influenza virus, and 36.7% believed that lactating mothers did not need to be vaccinated either.

Women's experience with vaccination is also an important consideration for their unwillingness to continue [166] . It was found that discomfort is a key factor affecting the willingness of women to vaccinate against influenza [167] . The main reasons are discomfort in response to vaccination, feelings toward previous vaccinations, and other factors belonging to personal and physical feelings. Xiao Huixin et al. pointed out that the willingness to vaccinate is consistent with the adverse reactions caused by 56.0% of influenza vaccinations [168] . Guo Xiue et al. pointed out that the rate of continuous vaccination cross two years accounts for 76.9%, but those who had been vaccinated for two consecutive years were no longer willing to do so, primarily due to feelings associated with vaccination during the previous year [169] . In addition, Su Bingguang and other scholars investigated 494 nurses, and 50.8% of the unwillingness to vaccinate was related to bad experiences with side effects after the injection [170] . In terms of women vaccination, willingness is related to the way vaccination is delivered. Research shows that the women's willingness to change the vaccine delivery method will increase by 70.4%, of whom 4.1% hope to provide a vaccine with four valence and multiple combinations, and 28.5% hope to provide an oral or nasal spray to J o u r n a l P r e -p r o o f replace the injection, however, 54.1% chose a brand of being trusted, of which usually made by foreign factories [171] .

The current vaccination policies are formulated by the state. For example, the measles vaccination policy is to wait until the antibodies from the mother disappear in the baby, so the vaccination time in advanced countries is 12-15 weeks of age. In low-income countries, it is nine months [172] .

The European Institute for Gender Equality (EIGE) specifically mentioned that the research and development process of new COVID-19 vaccines should pay attention to gender differences. Clinical trials must include men and women to eliminate gender blindness in medical research. This will help researchers understand the effectiveness and impact of possible vaccines on different genders, and it will also encourage them to pay attention to women's health rights and interests. Some research results show that in order to improve the vaccination rate, we need to change the way vaccines are delivered. For example, we might use tetravalent vaccines or oral administration. Nasal sprays and needle-free skin injections to reduce the occurrence of uncomfortable symptoms are other methods to improve availability and willingness. To improve the attitude and awareness toward vaccines, medical institutions J o u r n a l P r e -p r o o f can implement educational courses and advocacy activities to help people understand the safety of domestic or foreign vaccines [173, 174] . In addition, it is necessary to establish a convenient vaccination process to avoid unwillingness due to inconvenience or time-consuming vaccinations. Meanwhile, it is also necessary to actively contact people and assist in helping them understand the repercussions for not being vaccinated, which can improve the vaccination rate [175] .

During the spread of COVID-19, women have suffered more pressure and a higher physiological load than men, and they have also suffered more from the threat of infection. 

COVID-19 pandemic: Lessons learned and future directions

Updated Approaches against SARS-CoV-2

Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)

Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines

Responding to Covid-19 -A Once-in-a-Century Pandemic?

Inequality & COVID-19: The Forgotten Vulnerable

COVID-19 Exacerbating Inequalities in the US

Impact of sex and gender on COVID-19 outcomes in Europe

Sex Differences in Mortality from COVID-19

Pandemic: Are Men Vulnerable and Women Protected? JACC Case Rep

Why Viral (SARS, Ebola and AIDS) Epidemics Now?

SARS vaccine: progress and challenge

Animal coronavirus vaccines: lessons for SARS

Management of pregnant women infected with COVID-19

Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study

The COVID-19 vaccine development landscape

Safety, tolerability, and J o u r n a l P r e -p r o o f immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly

A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community

Influenza vaccination and medical care utilization for the community elderly in Taiwan

The effectiveness of influenza vaccination of the elderly lived in non-institutionalized in Taiwan

Why does COVID-19 disproportionately affect older people?

Influenza Vaccination Coverage Rates, Knowledge, Attitudes, and Beliefs in Jordan: A Comprehensive Study. Viral Immunol

Differences in national influenza vaccination policies across the European Union

Impact of influenza vaccination on seasonal mortality in the US elderly population

COVID-19 vaccine development and the way forward

Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals

Antibody Induction by Influenza Vaccines in the Elderly: A Review of the Literature

Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic

Events supposedly attributable to vaccination or immunization J o u r n a l P r e -p r o o f during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean

An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11

Expansion of seasonal influenza vaccination in the Americas

Sex differences in autoimmune disease

Sex differences in immune responses

Sex drives dimorphic immune responses to viral infections

A chemokine-driven positive feedback loop organizes lymphoid follicles

A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic

A GPR174-CCL21 module imparts sexual dimorphism to humoral immunity

Why aren't women choosing STEM academic jobs? Observations from a small-group discussion at the

Sex and Gender Differences in the Outcomes of Vaccination over the Life Course

Considering BCG vaccination to reduce the impact of COVID-19

Immunization, vaccines: past and future

Sex-based differences in immune function and responses to vaccination

Infections reveal inequality between the sexes

CD200 receptor controls sex-specific TLR7 responses to viral infection

Editorial: Sex Hormones and Gender Differences in Immune Responses

The Vaccine Safety Datalink: a model for monitoring immunization safety

Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network

Measles Antibody Levels in Young Infants

Prevalence of Protective Measles Virus Antibody Levels in Umbilical Cord Blood Samples and Sera of Mothers and Transplacental Transport Ratio in Turkey

The declining antibody level of measles virus in China population

Reducing measles mortality, reducing J o u r n a l P r e -p r o o f child mortality

Achieving the goal for global measles mortality

chez les garçons et les hommes: actualités et recommandations [HPV vaccination in boys and men: update and recommendations

A Qualitative Analysis of Young Sexual Minority Men's Perspectives on Human Papillomavirus Vaccination

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

Zika virus-like particle (VLP) based vaccine

Efficient expression of enterovirus 71 based on virus-like particles vaccine

Comment on "Will HPV Vaccination Prevent Cervical Cancer

Human Papillomavirus Research: Where Should We Place Our Bets?

HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis

Update on Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations

Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention. Immunization Update: The Latest ACIP Recommendations

Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years

Vaccination greatly reduces disease, disability, death and inequity worldwide

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

The global impact of noncommunicable diseases: estimates and projections

Overview of the benefits and potential issues of the nonavalent HPV vaccine

Autonomic Dysfunction and HPV Immunization: An Overview

Oxford Vaccine Group

SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19)

SARS-CoV-2 Receptor and Regulator of the

Celebrating the 20th Anniversary of the Discovery of ACE2

Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection

Expression of the COVID-19 receptor ACE2 in the human conjunctiva

ACE and ACE2: A Tale of Two Enzymes

Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients

Gender differences in COVID-19 infection

The estrogen effect on upper and lower airways

Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): A review

Middle East respiratory syndrome coronavirus

Purified coronavirus spike protein nano-particles induce coronavirus neutralizing antibodies in mice

Sex Hormones in Acquired Immunity and Autoimmune Disease

How sex and age affect immune responses, susceptibility to infections, and response to vaccination

Delivery of fetus death with misoprostol in a pregnant woman with H7N9 avian influenza A virus pneumonia and ARDS

Child mortality after high-titre measles vaccines: prospective study in Senegal

Child mortality following standard, medium or high titre measles immunization in West Africa

Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal

500 children vaccinated against measles

Accessed 31

Dermatological signs and symptoms of measles: a prospective case series and comparison with the literature

Assessment of Measles Immunity Among Infants in Maputo City

Histoire et principes de la vaccination

Noninvasive vaccination against infectious diseases

Available candidate vaccine viruses and potency testing reagents

Current status of mumps and mumps vaccine in the United States

Ethical considerations for epidemic vaccine trials

Design considerations for early-phase clinical trials of immune-oncology agents

New ethical considerations in vaccine trials

B cells engineered to express pathogen-specific antibodies protect against infection

The case for pathogen-specific therapy

Evaluating frequency and quality of pathogen-specific T cells

Cheaper HPV vaccines needed

Vaccine impact: Benefits for human health

Is it now the time to plan for global gender-neutral vaccination

Estimates of SARS death rates revised upward. The Center for Infectious Disease Research and Policy (CIDRAP)

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model

Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels

Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications

Parental Refusal of Childhood Vaccines and Medical Neglect Laws

Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature

Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation

Ethnic differences in human papillomavirus awareness and vaccine acceptability

Development and validation of measures to evaluate adolescents' knowledge about human papillomavirus (HPV), involvement in HPV vaccine decision-making, self-efficacy to receive the vaccine and fear and anxiety

Ethnically diverse female university students' knowledge and attitudes toward human papillomavirus (HPV), HPV vaccination and cervical cancer

Going with the Grain of Cognition: Applying Insights from Psychology to Build Support for Childhood Vaccination

Vaccine hesitancy: Causes, consequences, and a call to action

Is the MMR vaccine safe?

Vaccine-preventable disease control in the People's Republic of China

Effect of seasonality on the dynamics of an imitation--based vaccination model with public health intervention

Antibody Transmission From Mother to Fetus

The repertoire of maternal anti-viral antibodies in human newborns

Passive Protection against Respiratory Syncytial Virus Disease in Infants: The Role of Maternal Antibody

European Vaccine Manufacturers (EVM) Influenza Working Group. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges. Influenza Other Respir Viruses

Impfungen in der Schwangerschaft

Influenza Vaccination, Pregnancy Safety, and Risk of Early Pregnancy Loss

Influenza immunization during pregnancy: Benefits for mother and infant

Influenza vaccination during pregnancy and its usefulness to mothers and their young infants

Vaccine Adverse Events: Separating Myth from Reality

Identifying and addressing vaccine hesitancy

Vaccine Hesitancy: Where We Are and Where We Are Going

Rubella-induced congenital defects and rubella immunization

Vaccine side effects: fact and fiction

Update: vaccine side effects, adverse reactions, contraindications, and precautions-recommendations of the Advisory Committee on Immunization Practices (ACIP)

SAGE Working Group on Vaccine Hesitancy. Strategies intended to address vaccine hesitancy: Review of published reviews

Factors Related to Chinese Parents' HPV Vaccination Intention for Children

Vaccination greatly reduces disease, disability, death and inequity worldwide

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)

Vaccine refusal -what we need to know

Human papillomavirus vaccination coverage among Greek higher education female students and predictors of vaccine uptake

Do Maternal Living Arrangements Influence the Vaccination Status of Children Age 12-23 Months? A Data Analysis of Demographic Health Surveys 2010-11 from Zimbabwe

Factors associated with HPV vaccine uptake in teenage girls: a systematic review

Negative attitude of highly educated parents and health care workers towards future vaccinations in the Dutch childhood vaccination program

Participation in and attitude towards the national immunization program in the Netherlands: data from population-based questionnaires

Knowledge and Attitudes of Postpartum Mothers towards Immunization of Their Children in a Lithuanian Tertiary Teaching Hospital

Adolescent Participation in HPV Vaccine Clinical Trials: Are Parents Willing?

HPV infection awareness and self-reported HPV vaccination coverage in female adolescent students in two German cities

HPV vaccine awareness and willingness of first-year students entering university in Western Turkey

Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation

Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females

The COVID-19 pandemic and mental health impacts

Vaccine impact: Benefits for human health

Vaccines to Children: Protective Effect and Adverse Events: A Systematic Review. Stockholm: Swedish Council on Health Technology Assessment (SBU)

Human papillomavirus vaccination intentions and uptake in college women

SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward. Camb Q Healthc Ethics

Low vaccination in rural Sindh, Pakistan: A case of refusal, ignorance or access?

Analysis of adverse reaction assessment questionnaire for staff of medical institutions after influenza vaccination

A Survey on Cognition of and Attitudes towards Influenza, Influenza Vaccine, and Influenza Vaccination Behavior among Healthcare Workers

The Relationship J o u r n a l P r e -p r o o f between Knowledge and Practice toward the Acceptance of New Flu Vaccine among Nurses

HPV vaccination intent and willingness to pay for 2-,4-, and 9-valent HPV vaccines: A study of adult women aged 27-45 years in China

Ethics and Childhood Vaccination Policy in the United States

EIGE launches webpage on COVID-19 and gender equality

Educating Vaccionation Competence Project (EDUVAC)

Influenza vaccinations: older adults' decision-making process